文献速递其他结缔组织病

系统性硬化症患者循环及纯化IgG中缺乏靶向血管紧张素II受体1型和内皮素-1A型受体的功能性自身抗体

Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin-1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2025-01-27

本研究旨在复制既往关于系统性硬化症(SSc)中存在靶向AT1和ETAR功能性自身抗体的发现。采用实时细胞分析仪、qPCR和细胞因子ELISA评估纯化SSc IgG(n=18)的受体特异性功能,并开发新型蛋白捕获试验检测SSc患者(n=28)和健康供者(n=14)血浆中AT1结合自身抗体。结果未发现AT1或ETAR依赖性内皮细胞激活,SSc IgG未诱导受体激活或改变GPCR信号,血浆中未检测到AT1结合自身抗体。

要点

  • 纯化SSc IgG(n=18)未引起AT1或ETAR依赖性内皮细胞激活。
  • SSc IgG未诱导受体激活或改变受体过表达模型中的GPCR信号。
  • SSc患者血浆(n=28)中未检测到AT1结合自身抗体。

核心结论

  • 本研究未提供证据支持纯化SSc IgG中存在AT1或ETAR激活型自身抗体,也未支持SSc患者循环中存在AT1结合自身抗体。

研究设计与样本

  • 采用实时细胞分析仪、定量聚合酶链反应和细胞因子酶联免疫吸附试验评估纯化SSc IgG(n=18)的受体特异性功能特征。
  • 开发新型蛋白捕获试验,使用可溶性表位标记AT1检测SSc患者(n=28)和健康供者(n=14)血浆中的AT1结合自身抗体。

主要发现

  • 未发现AT1或ETAR依赖性内皮细胞激活的证据。
  • 在受体过表达模型中,SSc IgG刺激未诱导受体激活,也未改变激动剂刺激下的G蛋白偶联受体信号。
  • 使用表位标记可溶性AT1时,SSc患者血浆样本中未检测到AT1结合自身抗体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) is a rare but severe autoimmune disease characterized by immune dysregulation, fibrosis, and vasculopathy. Although previous studies have highlighted the presence of functional autoantibodies targeting the angiotensin II receptor type 1 (AT1) and endothelin-1 type A receptor (ETAR), leading to autoantibody-mediated receptor stimulation and subsequent activation of endothelial cells (ECs), a comprehensive understanding of the direct interaction between these autoantibodies and their receptors is currently lacking. Moreover, existing data confirming the presence of these autoantibodies in SSc often rely on similar methodologies and assays. Our aim was to replicate previous findings and to investigate the functional effects of IgG derived from patients with SSc (SSc IgG) on AT1 and ETAR signaling, the downstream EC response, and the presence of AT1-binding autoantibodies in circulation. METHODS: Quantitative polymerase chain reaction and cytokine enzyme-linked immunosorbent assay, alongside a real-time cell analyzer, were used to assess receptor-specific functional characteristics of purified SSc IgG (n = 18). Additionally, a novel protein capture assay using solubilized epitope-tagged AT1 was developed to detect AT1-binding autoantibodies in plasma samples from patients with SSc (n = 28) and healthy donors (n = 14). RESULTS: No evidence for EC activation in an AT1- or ETAR-dependent manner was revealed. Furthermore, stimulation with SSc IgG did not induce receptor activation or alter G protein-coupled receptor signaling on agonist stimulation in a model with receptor overexpression. Lastly, no AT1-binding autoantibodies were detected in plasma samples from patients with SSc when using epitope-tagged solubilized AT1. CONCLUSION: Overall, our study did not provide evidence to support the presence of AT1- or ETAR-activating autoantibodies in purified SSc IgG or AT1-binding autoantibodies in the circulation of patients with SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. van Oostveen WM, Hoekstra EM, Levarht EWN, et al. Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin-1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis. Arthritis Rheumatol. 2025. PMID: 39721751. doi:10.1002/art.43099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。